Clinical symptoms and cognitive functioning following adjunctive N-acetylcysteine in obsessive-compulsive disorder: a double-blind, placebo-controlled trial
Sanaz Askari, Shayan Eghdami, Mahla Tavasoli, Seyed Vahid Shariat, Masoomeh Yarahmadi, Atefeh Ghanbari Jolfaei, Elham Shirazi, Soode Tajik Esmaeeli, Mohammadreza Shalbafan · 2026
Read Clinical symptoms and cognitive functioning following adjunctive N-acetylcysteine in obsessive-compulsive disorder: a double-blind, placebo-controlled trial by Sanaz Askari, Shayan Eghdami, Mahla Tavasoli, Seyed Vahid Shariat, Masoomeh Yarahmadi, Atefeh Ghanbari Jolfaei, Elham Shirazi, Soode Tajik Esmaeeli, Mohammadreza Shalbafan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13635134.txt.
Description
Adding N-acetylcysteine, a glutamate-modulating antioxidant, to standard antidepressant treatment for obsessive-compulsive disorder is tested by Askari and colleagues. Obsessive-compulsive disorder often responds only partly to first-line serotonin drugs. Earlier add-on studies lacked standard drug dosing or cognitive measures. The team ran a twelve-week, double-blind, placebo-controlled trial in thirty-five adults with moderate to severe symptoms, all receiving high-dose sertraline plus either N-acetylcysteine or placebo.
The add-on group showed greater symptom reduction, driven mainly by obsessions. Compulsion scores improved similarly in both groups, and every patient in the add-on group reached the response threshold. Both groups improved on processing speed and attention, with no cognitive edge for the add-on. Askari and colleagues read the pilot as support for short-term use, while noting that larger trials must confirm the benefit.
Catalog record
| CREATOR | Sanaz Askari, Shayan Eghdami, Mahla Tavasoli, Seyed Vahid Shariat, Masoomeh Yarahmadi, Atefeh Ghanbari Jolfaei, Elham Shirazi, Soode Tajik Esmaeeli, Mohammadreza Shalbafan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |